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Abstract: All newborns require phylloquinone after birth to prevent vitamin K deficiency bleeding.
Babies born prematurely may be at particular risk of deficiency without adequate supplementation
during infancy. The main sources of phylloquinone in preterm babies during the neonatal period
are the prophylactic dose of phylloquinone given at birth, and that derived from parenteral and/or
enteral feeding. This observational study formed part of a prospective, multicentre, randomised,
controlled trial that examined the vitamin K status of preterm infants after random allocation to
one of three phylloquinone prophylactic regimens at birth (0.5 or 0.2 mg intramuscularly or 0.2 mg
intravenously). In this nutritional sub-study we quantified the proportional and total phylloquinone
intakes of preterm infants within the neonatal period from all sources. Almost all infants had
average daily phylloquinone intakes that were in excess of the currently recommended amounts.
In infants who did not receive parenteral nutrition, the bolus dose of phylloquinone given at
birth was the major source of phylloquinone intake, whereas in infants who received parenteral
nutrition, the intake from the parenteral preparation exceeded that from the bolus dose by a ratio
of approximately 3:1. Our study supports the concern of others that preterm infants who receive
current parenteral nutrition formulations may be receiving excessive vitamin K.
Keywords: phylloquinone; prophylaxis; prematurity; deficiency; bleeding; dietary; micronutrients;
supplement; nutrition
1. Introduction
Vitamin K-dependent coagulation factors are synthesised exclusively in the liver and so the
maintenance of adequate hepatic vitamin K reserves is essential for normal haemostasis. Preterm
as well as term babies are born with extremely low hepatic stores of vitamin K [1,2]. Unlike in
adults, the major hepatic form of vitamin K in neonates is phylloquinone (vitamin K1) which is also
the major form of the vitamin in human breast milk. After birth, the combination of low hepatic
reserves and relatively low concentrations of phylloquinone in breast milk (compared to formula
milks) places the breast-fed infant at increased risk of developing vitamin K deficiency. They are
consequently dependent upon adequate intakes of vitamin K postnatally and during early infancy
to keep them healthy. Supplementary vitamin K prophylaxis is offered at birth to protect against
vitamin K deficiency bleeding (VKDB), a now rare but still potentially lethal disorder which may
cause devastating brain injury and lifelong impairment in survivors [3–5]. Preterm infants may be at
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higher risk of developing VKDB without adequate ongoing phylloquinone intakes following birth [6],
so a baseline understanding of their current typical intakes from various sources during the neonatal
period is clearly important.
In both term and preterm infants the very large bolus dose of phylloquinone given
prophylactically at birth is considered to be the major source of phylloquinone in early infancy [7,8],
and, therefore, to provide the mainstay of protection provided against VKDB during early infancy.
Preterm neonates receive an on-going supply of phylloquinone from dietary sources, including from
enteral and often parenteral feeding. No previous study has reported in detail the total phylloquinone
intakes of preterm infants from all the various sources during their first weeks of life. The aims of this
study were: (i) to quantify phylloquinone intake by preterm infants from all sources during the first
postnatal weeks of life; and (ii) to assess the relative contribution of the various sources to the total
phylloquinone intake of preterm infants during the neonatal period.
2. Experimental Section
2.1. Study Design
This observational study was done as part of a prospective, multicentre, randomised controlled
trial that examined the vitamin K status of preterm infants after random allocation to one of three
phylloquinone prophylactic regimens at birth [9]. The setting was three neonatal intensive care
units (NICUs) in the United Kingdom (UK). The present study reports the detailed phylloquinone
intakes of these infants during the first weeks after birth. Data on the functional outcome measures
of phylloquinone status and metabolism in this cohort, including undercarboxylated prothrombin
(PIVKA-II), prothrombin time, and factor II concentrations, were reported previously [9]. Assessment
of other vitamin-K dependent proteins (such as osteocalcin and matrix Gla protein) was beyond the
scope of the study.
2.2. Subjects
Infants eligible for inclusion were born at a gestational age of <32 completed weeks and
admitted to one of the three participating NICUs. Exclusion criteria included fetal intracranial
haemorrhage suspected antenatally, history of maternal antiplatelet antibodies or alloimmune
thrombocytopenia, maternal drug treatment with known vitamin K antagonists, life-threatening
congenital abnormality, and marked bruising present from birth. Infants with bowel diseases
(such as necrotising enterocolitis) or other expected complications of prematurity were not excluded
or discontinued from the study. Written parental consent was obtained for inclusion, and the period
of recruitment was between November 2001 and February 2003.
2.3. Sources of Vitamin K Intake
There are only three prospective sources of phylloquinone intake by preterm infants during the
neonatal period: (i) the prophylactic bolus dose received soon after birth and any extra bolus doses
given while in the NICU; (ii) enteral milk feeds and human milk fortifiers (HMFs); and (iii) parenteral
nutrition (PN).
2.3.1. Prophylactic Phylloquinone Formulation and Dose
The phylloquinone preparation provided for prophylaxis and for any subsequent bolus dose
for infants in this study was Konakionr Neonatal Ampoules (Roche Ltd, Basel, Switzerland). This
formulation contained phytomenadione 2 mg/mL and had Cremophor EL (BASF AG, Ludwigshafen,
Germany) as the solubilising excipient. Although unlicensed for use in preterm infants, this vitamin
K formulation was at the time the commonest preparation used for prophylaxis in the UK [10].
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For the main study [2,9], infants were randomly allocated to receive one of three vitamin K
prophylaxis regimens within a few hours of birth: phylloquinone 0.5 mg intramuscularly (IM),
0.2 mg IM, or 0.2 mg intravenously (IV). As a safety provision, the study protocol provided that
a 0.2 mg IM additional bolus dose of phylloquinone would be given during the study period to
any infant with abnormal coagulation values or clinical bleeding in case these findings represented
vitamin K deficiency.
2.3.2. Enteral Feeding and Human Milk Fortifiers
The introduction and grading of enteral feeds proceeded in line with standard practices.
In general, small “trophic” volumes (totalling ~20 mL/kg/day) of colostrum/human milk and/or
a preterm milk formula were commenced within the first few days postnatal. Maternal expression
of breast milk was actively encouraged, and expressed breast milk (EBM) was the preferred milk
feed for preterm infants at all participating neonatal units. Bolus aliquots of milk were given via a
nasogastric tube, initially on an hourly basis. Any increment in the feed volume was a decision of
the clinical ward round and would depend upon an infant’s stability and any recent history of feed
tolerance. Infants were considered to have established full enteral feeds when they were tolerating a
volume of at least 150 mL/kg/day of milk and no longer on PN. An infant who tolerated the gradual
feed increase without event or setback would potentially establish full feeds by 7–10 days postnatal.
It was standard clinical practice at all three participating NICUs to add HMF routinely to breast
milk once the full enteral feed volume of 150 mL/kg/day was attained. Three commercially-available
HMFs were available in the UK during the study period. Infants at the participating units all received
Eoprotin HMF (Nutricia Ltd., Trowbridge, UK). Coincidentally, a new formulation of Eoprotin with a
higher phylloquinone content was introduced nationally in the UK during the study period. Initially
one scoop was given per 100 mL of breast milk, and this was graded up to three scoops (old
Eoprotin formulation) or four scoops (new Eoprotin formulation) on successive days as tolerated.
Infants discharged to neonatal centres outside of the three trial centres prior to study completion who
subsequently received a different HMF had their phylloquinone intake calculated according to the
actual fortifier received.
2.3.3. Parenteral Nutrition
Administration of PN solution was routine for the sickest neonates in the participating NICUs.
It was generally reserved for all very preterm infants (less than ~29 weeks’ gestation), extremely low
birth weight infants (ELBW; <1000 g), and also any other neonate that was considered unlikely to
achieve full enteral feeding by 7–10 days postnatal. It was expected that many of the more mature
and heavier preterm infants in the study group would not require PN.
PN was usually commenced within the first three days of life. The daily volume of lipid infused
was routinely graded up over the first three days to minimise fat intolerance and hyperlipidaemia.
The phylloquinone-containing components of the PN solution were 20% Intralipidr, an intravenous
fat emulsion, and Vitlipid N Infantr, a fat-soluble vitamin emulsion (Fresenius Kabi Ltd, Runcorn,
Cheshire, UK). Nursing charts recorded the dates when PN began and ended, and also the exact daily
volumes of the respective PN solutions delivered to each infant.
2.4. Assessment of Phylloquinone Intake
Phylloquinone intakes from all sources were calculated between birth and the date that the infant
had tolerated full enteral feeds (i.e., ě150 mL/kg/day of milk) for a continuous full 2-week period,
the latter date being considered the date of “study completion”. The total vitamin intake was thus
calculated for each enrolled infant between birth and the date that full enteral feeds had been tolerated
for two weeks.
Each infant’s absolute phylloquinone intake between birth and study completion was calculated
from the sum amounts received from: (i) allocated prophylactic phylloquinone dose and any extra
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bolus phylloquinone doses given during the study period, obtained from review of the prescription
charts; (ii) daily enteral feed volumes and HMF, obtained from the daily nursing charts; and (iii) PN
intake, with daily volumes of Intralipid and Vitlipid received being obtained from the PN prescription
charts and the nursing infusion administration charts.
An average daily phylloquinone intake was calculated for each infant from its total
phylloquinone intake (expressed in µg/kg, using the infant’s weight at completion of the study)
divided by the number of days from birth to study completion. The phylloquinone intake from
enteral feeds was calculated from the actual milk types and volumes fed to each infant between birth
and study completion, as recorded on the neonatal nursing charts.
2.4.1. Phylloquinone Content of Milk Feeds and Fortifier
Table 1 shows the phylloquinone content of human preterm breast milk, and of the
preterm artificial milk formulae that were available in the UK during the study period.
The values for phylloquinone content of term infant human breast milk and term infant milk
formulae are also provided for comparison purposes. Milk formulae phylloquinone contents
are compiled from the various manufacturers’ contemporaneous data sheets. Values for the
phylloquinone content of HMF-fortified preterm breast milk are also provided; these are
based upon the manufacturer-published phylloquinone content of the various HMFs that were
commercially-available during the study period, and upon the mean phylloquinone concentration
value reported for preterm EBM. The value for mean phylloquinone concentration of human preterm
EBM (3.0 µg/L) derives from a study of human milk obtained on postnatal one day from mothers
of preterm infants prior to maternal phylloquinone supplementation [11]. To date this study of
Bolisetty et al. [11] remains the only known study in which breast milk phylloquinone concentrations
have been measured in mothers of preterm infants. Nevertheless, this mean value compares well to
the mean concentration of phylloquinone in mature human breast milk (2.1 µg/L) from mothers
of term infants reported by Haroon et al. [12], and to the mean value (2.5 µg/L) that was used
in the calculation of the Adequate Intake (AI) by the Food and Nutrition Board [7]. Addition of
HMF to EBM provided a total phylloquinone concentration of 5–66 µg/L depending on brand used
(Table 1). Artificial preterm milk formulae provided 40–66 µg/L of phylloquinone depending on
brand. These values were used to calculate exact phylloquinone intakes from the enteral feeds for all
study individuals up to completion of the study.
Table 1. Phylloquinone content of human milk, commercial milk formulae, and fortifiers.
Nutrient Phylloquinone Content (µg/100 mL) Phylloquinone Content (µg/L)
Human Milk
Term colostrum a 0.23 2.3
Term mature EBM a 0.21 2.1
Preterm colostrum/EBM b 0.30 3.0
Formula Milks
PreAptamil 6.6 66
Aptamil 4.0 40
Nutriprem 1 6.6 66
Nutriprem 2 5.9 59
SMA Low Birth Weight 8.0 80
SMA Gold 6.7 67
C + G Premium 5.1 51
C + G Plus 5.0 50
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Table 1. Cont.
Nutrient Phylloquinone Content (µg/100 mL) Phylloquinone Content (µg/L)
Human Milk Fortifiers
Eoprotin (old formulation) 0.2 per 3 scoops (3 g powder) c 2
Eoprotin (new formulation) 6.3 per 4 scoops (4.2 g powder) c 63
Nutriprem HMF 6.2 per 2 sachets (4.2 g powder) c 62
SMA Breast Milk Fortifier 11.0 per 2 sachets (4 g powder) c 110
Fortified EBM d
Eoprotin old formulation 0.5 5
Eoprotin new formulation 6.6 66
Nutriprem HMF 6.5 65
SMA HMF 11.3 113
EBM, expressed breast milk; HMF, human milk fortifier. a Analysis of colostrum and breast milk obtained
within five days post-partum, from Haroon et al. [12]; b Mean preterm EBM concentration on the first postnatal
day in unsupplemented mothers, from Bolisetty et al. [11]; c Quantities recommended by manufacturers for
addition to each 100 mL of human milk; d Values listed refer to content of fortified human milk after adding
the recommended amount of HMF according to manufacturers’ instructions
2.4.2. Phylloquinone Content of Parenteral Nutrition Solution
The phylloquinone content of Vitlipid N Infant (fat soluble vitamin emulsion) was 20 mg/L.
That of 20% Intralipid IV fat emulsion varied between batches, and ranged from 0.50 to
0.77 mg/L [13]; for calculation purposes a figure of 0.6 mg/L was used. Infants on PN received
4 mL/kg of Vitlipid and 5–15 mL/kg of 20% Intralipid per day, providing daily phylloquinone
supplementation of 80 µg/kg and 3–9 µg/kg respectively.
2.4.3. Calculation of Total and Proportional Phylloquinone Intake from All Sources
The average daily phylloquinone intake was calculated for each infant from the total
phylloquinone intake (expressed as µg/kg body weight at study completion) divided by number of
days between birth and study completion. The proportional intake of phylloquinone from each route
was also assessed: for each infant the contribution to overall total intake from each phylloquinone
source was expressed as a percentage of total intake. In addition to calculating the proportional
intake for all infants who completed the study (because not all preterm infants required or received
PN feeding) the proportional intake was calculated separately for infants who received PN and for
infants who did not receive any PN.
2.4.4. Statistical Analysis
Infants who died before study completion were excluded from analysis. Data for all
randomised infants who completed the study were analysed using StatsDirect statistical software
(www.statsdirect.com) version 2.4.5. The Mann-Whitney U test was used to compare phylloquinone
intakes between the three randomisation cohorts, and a p-value of <0.05 was considered
statistically significant.
2.5. Ethics Approvals
The study received prior ethical review board approval from Salford and Trafford Local Research
Ethics Committee on 5 November 2001 (Project No. 01198). Further Research Ethics Committee
approvals were given on 10 July 2002 and on 10 December 2002 for extension of the study to two
additional sites.
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3. Results
3.1. Baseline Characteristics
Of 98 infants randomised to the main trial [2,9], 15 died before study completion and three
infants with incomplete data were excluded from the analysis. All deaths were related to the common
complications of prematurity and no infant in the study had vitamin K deficiency bleeding [9].
A total of 80 infants completed the study. Table 2 shows their baseline characteristics, including
feeding characteristics, overall and subgrouped according to initial allocated dose of phylloquinone
prophylaxis. There were no significant differences between subgroups for any of these baseline
characteristics. As already reported, all infants had satisfactory vitamin K status at study completion
and there were no significant differences in any functional outcome measures of phylloquinone status
and metabolism between the subgroups in this cohort [9]. No infant suffered any suspected adverse
event or reaction in relation to phylloquinone dosage or its route of administration. There were no
differences between sub-groups in incidence of significant intraventricular haemorrhage (n = 6 infants
overall, p = 0.9), other significant bleeding, such as gastro-intestinal or pulmonary (n = 7 infants
overall, p = 0.2), or numbers transfused with fresh frozen plasma during the study (n = 7 infants
overall, p = 0.7).
Table 2. Baseline characteristics of the n = 80 infants who completed the study and subgroups
according to initial phylloquinone prophylaxis regimen.
Characteristic All Infants (n = 80) 0.5 mg IM (n = 28) 0.2 mg IM (n = 26) 0.2 mg IV (n = 26)
Gestational Age, weeks 29.4 (22.4–31.9) 29.0 (24.1–31.9) 29.9 (24.0–31.7) 29.6 (22.4–31.4)
Birth Weight, g 1092 (454–1910) 1033 (454–1910) 1143 (534–1910) 1203 (575–1892)
Male gender, n 36 (45%) 10 (36%) 13 (50%) 13 (50%)
Received any PN, n 56 (70%) 18 (64%) 17 (65%) 21 (81%)
Duration of PN a, days
median (range) (IQR) 10 (3–78) (7–17) 9 (4–78) (7–13) 10 (5–29) (9–21) 9 (3–48) (5–18)
Postnatal age reached full
enteral feeds, days 10 (4–80) 9 (4–80) 12 (4–43) 11 (4–49)
Postnatal age at study
completion, days 25 (17–90) 24 (19–90) 26 (19–58) 26 (17–64)
Weight at study
completion, g 1495 (600–2710) 1281 (605–2650) 1595 (600–2270) 1572 (612–2710)
Data are median (range) unless indicated. IM, intramuscular; IV, intravenous; PN, parenteral nutrition;
IQR, inter-quartile range. a Data shown here include only babies who received any period of PN. There were
no statistically significant differences between any subgroups for any of the baseline characteristics shown.
3.2. Total Phylloquinone Intakes
Table 3 shows total phylloquinone intakes from all sources between birth and study completion
overall and for the subgroups. There were no significant differences in absolute phylloquinone
intakes from all sources between the three study groups at study completion. However, after
correcting for birth weight and days to study completion, the average daily intake of phylloquinone
adjusted for birth weight was significantly lower for infants who had received 0.2 mg boluses at birth
(p < 0.05).
8313
Nutrients 2015, 7, 8308–8320
Table 3. Phylloquinone intakes from all sources between birth and study completion (adapted from
Clarke et al. [9], with permission).
Phylloquinone Intake (µg) All infants (n = 80) 0.5 mg IM (n = 28) 0.2 mg IM (n = 26) 0.2 mg IV (n = 26)
Via bolus doses
Mean (SD) 378 (256) 629 (264) 238 (80) * 246 (130) *
Median (range) 200 (200–1500) 500 (500–1500) 200 (200–400) * 200 (200–800)
From PN :
Mean (SD) 784 (939) 610 (972) 754 (768) 1001 (1045)
Median (range) 542 (0–5071) 440 (0–5071) 674 (0–2441) 713 (0–3895)
Via enteral feeds
Mean (SD) 124 (90) 118 (85) 125 (97) 131 (91)
Median (range) 133 (2–340) 116 (2–340) 122 (6–304) 145 (8–300)
Total phylloquinone intake µg
Mean (SD) 1286 (1025) 1357 (1133) 1118 (775) 1378 (1136)
Median (range) 1011 (214–6574) 1038 (507–6574) 958 (332–2730) 1020 (214–4822)
µg/kg
Mean (SD) 914 (597) 1070 (633) 808 (591) 853 (548)
Median (range) 775 (141–2594) 1048 (408–2594) 699 (173–2057) 704 (141–2343)
µg/kg/day
Mean (SD) 30 (15) 37 (15) 26 (15) ; 27 (11) ;
Median (range) 28 (7–75) 39 (18–75) 27 (8–55) ; 27 (7–65) ;
SD, standard deviation. : Includes infants who received any period of PN as well as those who did not
receive PN; * Versus 0.5 mg IM group, p < 0.001; ; Versus 0.5 mg IM group, p < 0.05.
3.2.1. Phylloquinone Intakes According to Parenteral Nutrition Administration
Table 4 shows the total phylloquinone intake from all sources in study infants who received any
period of PN and completed the study (n = 56). PN-derived phylloquinone intake in these 56 infants
was comparable in the 0.5 mg IM (n = 18) and 0.2 mg IV (n = 21) groups, and slightly higher in the
0.2 mg IM group (n = 17).
Table 5 shows total phylloquinone intakes by route confined to study infants who did not receive
any PN (n = 24).
Table 4. Relative intakes of phylloquinone from all sources together with total intakes at study
completion in infants who received parenteral nutrition.
Phylloquinone Intake (µg) All Infants Given PN (n = 56) 0.5 mg IM (n = 18) 0.2 mg IM (n = 17) 0.2 mg IV (n = 21)
Via bolus doses
Mean (SD) 391 (277) 672 (303) 259 (94) * 275 (143) *
Median (range) 200 (200–1500) 500 (500–1500) 200 (200–400) * 200 (200–800) *
From PN
Mean (SD) 1120 (940) 950 (1077) 1153 (658) : 1240 (1027)
Median (range) 759 (305–5071) 589 (350–5071) 767 (515–2441) : 946 (305–3895)
Via enteral feeds
Mean (SD) 101 (80) 97 (63) 80 (82) 120 (89)
Median (range) 94 (2–304) 105 (2–198) 79 (6–304) 142 (8–300)
Total phylloquinone intake µg
Mean (SD) 1612 (1066) 1719 (1280) 1492 (714) 1617 (1140)
Median (range) 1234 (596–6574) 1423 (956–6574) 1189 (771–2730) 1240 (596–4822)
µg/kg
Mean (SD) 1168 (535) 1410 (540) 1119 (498) 1000 (506) ;
Median (range) 1136 (438–2594) 1269 (721–2594) 971 (529–2057) 813 (438–2343) ;
µg/kg/day
Mean (SD) 37 (13) 46 (12) 34 (11) ; 30 (10) *
Median (range) 33 (18–75) 44 (28–75) 33 (19–55) ; 29 (18–65) *
Statistically-significant comparisons (using Mann-Whitney U test) are shown thus: * versus 0.5 mg IM group,
p < 0.0001; : Versus 0.5 mg IM group, p < 0.05; ; Versus 0.5 mg IM group, p < 0.01.
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Table 5. Relative intakes of phylloquinone from bolus doses and enteral feeds together with total
intakes at study completion for infants who did not receive parenteral nutrition.
Phylloquinone Intake (µg) All Infants Not Given PN (n = 24) 0.5 mg IM (n = 10) 0.2 mg IM (n = 9) 0.2 mg IV (n = 5)
Via bolus doses
Mean (SD) 346 (202) 550 (158) 200 (NA) * 200 (NA) :
Median (range) 200 (200–1000) 500 (500–1000) 200 (NA) * 200 (NA) :
Via enteral feeds
Mean (SD) 181 (88) 156 (107) 212 (55) 176 (94)
Median (range) 195 (7–340) 149 (7–340) 214 (132–292) 208 (14–254)
Total phylloquinone intake µg
Mean (SD) 527 (187) 706 (145) 412 (55) * 376 (94) :
Median (range) 466 (214–1016) 690 (507–1016) 414 (332–492) * 408 (214–454) :
µg/kg
Mean (SD) 322 (124) 458 (48) 220 (27) * 233 (54) :
Median (range) 251 (141–562) 439 (408–562) 215 (173–249) * 249 (141-284) :
µg/kg/day
Mean (SD) 15 (6) 22 (3) 10 (1) * 12 (4) :
Median (range) 13 (7–25) 21 (18–25) 10 (8–12) * 13 (7–17) :
NA, not applicable because all infants received 0.2 mg dose. Statistically-significant comparisons (using
Mann-Whitney U test) are shown thus: * versus 0.5 mg IM group, p < 0.0001; : Versus 0.5 mg IM group,
p < 0.001.
3.2.2. Proportional Contribution of Various Sources to Overall Phylloquinone Intakes
Table 6 shows the proportional intake of phylloquinone from each route as a percentage of
the total intake, for all infants and for the subgroups. Analysis of the proportional intake of
phylloquinone from the various routes shows that for the infants receiving 0.5 mg phylloquinone
after delivery and who received PN, the bolus dose comprised ~40% of total phylloquinone intake
over the study period, while PN comprised ~50% of intake, and enteral feeding <10% of intake. In
contrast for the 0.2 mg groups, only ~20% of the total phylloquinone intake in the study period came
from the bolus prophylaxis dose, whereas 70% came from PN, and <10% came from enteral feeding.
Table 6. Proportional intake of phylloquinone from each route from birth until study completion as a
percentage of the total intake.
Proportional Phylloquinone Intake All Infants 0.5 mg IM 0.2 mg IM 0.2 mg IV
All Infants n = 80 n = 28 n = 26 n = 26
% Via bolus doses
Mean (SD) 38 (23) 56 (21) 30 (16) * 27 (19) *
Median (range) 33 (5–99) 52 (23–99) 22 (7–60) * 20 (5–94) *
% From PN
Mean (SD) 46 (33) 32 (26) 49 (37) : 57 (31) *
Median (range) 56 (0–92) 37 (0–77) 69 (0–89) : 68 (0–92) *
% Via enteral feeds
Mean (SD) 17 (18) 12 (11) 21 (23) 16 (17)
Median (range) 8 (0–59) 8 (0–41) 10 (0–59) 8 (0–56)
Infants given PN n = 56 n = 18 n = 17 n = 21
% Via bolus doses
Mean (SD) 27 (14) 43 (11) 20 (8) * 19 (8) *
Median (range) 23 (5–64) 45 (23–64) 19 (7–42) * 17 (5–34) *
% From PN
Mean (SD) 65 (16) 50 (13) 75 (10) * 71 (13) *
Median (range) 68 (28–92) 50 (28–77) 78 (54–89) * 74 (43–92) *
% Via enteral feeds
Mean (SD) 8 (7) 7 (5) 6 (6) 10 (9)
Median (range) 6 (0–28) 7 (0–16) 3 (0–21) 8 (0–28)
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Table 6. Cont.
Infants not given PN n = 24 n = 10 n = 9 n = 5
% Via bolus doses
Mean (SD) 63 (18) 78 (13) 49 (7) * 57 (21) :
Median (range) 58 (41–99) 77 (60–99) 48 (41–60) * 49 (44–94) :
% Via enteral feds
Mean (SD) 37 (18) 22 (13) 51 (7) * 43 (21) :
Median (range) 42 (1–59) 23 (1–41) 52 (40–59) * 51 (7–56) :
Statistically-significant comparisons (using Mann-Whitney U test) are shown thus: * versus 0.5 mg IM group,
p < 0.0001; : Versus 0.5 mg IM group, p <0.05.
Considering infants who had not received any period of PN, the bolus dose for those receiving
0.5 mg phylloquinone after delivery represented ~80% of the total study intake (with enteral feeding
~20% of the total intake), whereas for the 0.2 mg groups the bolus dose and enteral feeding each
comprised ~50% of the total phylloquinone intake.
4. Discussion
This is the first study to describe in detail the absolute phylloquinone intake by preterm infants
from all sources during their first weeks of postnatal life. We quantified the relative proportional
intake of phylloquinone from the various nutritional routes for infants who received PN and for
those who did not receive PN. We found no differences in overall intakes between the three study
groups that had been randomly allocated different phylloquinone regimens at birth. However after
correcting for birth weight and days to study completion, the average daily intake of phylloquinone
adjusted for birth weight was significantly lower for infants who had received the lower dose
prophylactic bolus dose of 0.2 mg phylloquinone. We had speculated that the initial bolus doses of
phylloquinone given for prophylaxis at birth would assume less importance as a source of the vitamin
contributing to the overall intake at study completion, due to the increasing respective contributions
to overall phylloquinone intake derived from other nutritional (dietary) sources. In infants who
did not receive any PN, the bolus dose given at birth represented approximately 50% of the overall
phylloquinone intake at study completion, compared to only approximately 20% in infants who had
received PN.
Preterm infants represent a neglected group with respect to current knowledge of their
phylloquinone intakes and recommendations for their nutritional requirements. As pointed out by
Kumar et al. [14], published recommendations for vitamin K intakes and/or supplementation are
specific for all ages except for preterm infants. As a result, recommendations for preterm infants
are arbitrary and historically have ranged from 5 to 10 µg/kg/day in 1993 [15] and as high as
100 µg/kg/day in 1988 [16]. In this context it is important to note that the principles and knowledge
base of dietary recommendations have changed over time. For example, the recommendations of
5–10 µg/kg/day for preterm infants in 1993 [15] came out during the lifespan of the 10th Edition
of the US Food and Nutrition Board guidelines published in 1989, at which time they took the form
of Recommended Daily Allowances (RDA) instead of the current Dietary Reference Intakes (DRI).
At that time the RDA for term infants over the first six months was 5 µg/day, which in turn was
based on the adult RDA of 1 µg/kg/day [17]. This means that the 5–10 µg/kg/day recommendation
for preterm infants by Greer et al. [15] was 5–10 fold greater than the intake recommendations for
term infants at that time. More recent guidelines published in 2005 recommended a phylloquinone
intake of 8–10 µg/kg/day as an AI for preterm infants [18], representing the top end of the 1993
recommendations [15].
There is an inevitable degree of arbitrariness of recommendations even for healthy term infants.
In the current United States recommendations published in 2001, the AI for healthy term infants
is based on an average daily milk intake of 0.78 L and an average phylloquinone concentration in
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human milk of 2.5 µg/L [7]. This gave an AI of 2.0 µg/day after rounding [7]. The weak link in this
calculation as a precise AI value lies with the fairly wide variations in the reported concentrations
of phylloquinone in breast milk which taking the lower and upper values would result in estimated
phylloquinone intakes of ~0.5 µg/day and 2.5 µg/day respectively [8].
Another weakness of current recommendations is that they are based solely on the
phylloquinone content of breast milk. Although phylloquinone is the major vitamer of vitamin K
in breast milk, it also contains a member of the menaquinone series, namely menaquinone-4 (MK-4)
at concentrations that are about half that of phylloquinone [19,20]. There is also evidence that this
MK-4 in breast milk is derived from dietary phylloquinone [20]. Future neonatal AI recommendations
should also consider the contribution to intakes made by MK-4 as well as its potential contribution to
neonatal vitamin K status.
Whether the dietary guidelines have been in the form of an RDA or AI, a common underlying
assumption is that the infant is also given a prophylactic dose at birth in amounts recommended
by the relevant paediatric societies [7,17]. For any individual infant, the optimal daily ongoing
phylloquinone required from feeding will depend in part upon what prophylactic dose was given
at birth and any postnatal supplementation received from PN. However there is also likely to be
inter-individual variation in storage and metabolism.
For the purposes of discussion we have taken the most recent recommendation of
8–10 µg/kg/day [18] as a benchmark against which the phylloquinone intakes in this study
can be compared. The median phylloquinone intake for infants who completed this study was
approximately three-fold this recommended amount, and up to five to seven-fold more in some
infants (Table 3). For infants who received PN, there was little difference between allocation groups.
The median of the average phylloquinone intake was three to four times the recommended amount,
and all had an average phylloquinone intake that ranged between ~20–70 µg/kg/day, i.e., two to
seven times the daily recommendation (Table 4). For infants who did not receive any PN, the median
average daily intake received by 0.5 mg IM group infants was approximately twice that currently
recommended, whereas for infants in the 0.2 mg IM and 0.2 mg IV bolus groups the medians and
ranges of average daily intakes were remarkably close to the currently recommended intakes of
8–10 µg/kg/day (Table 5).
For infants who did not receive any PN, the bolus dose(s) of phylloquinone constituted the major
source of phylloquinone intake in the study period. In contrast, for infants who had received a period
of PN by far their major intake source was, somewhat surprisingly, that delivered by the PN solution.
For comparison, the ratio of median phylloquinone intake from PN to that from bolus doses was ~3:1.
In infants given PN, the median overall phylloquinone intake from enteral feeds was 6% (range:
0%–28%) of the total intake. In contrast in the infants not given PN the proportional intake from
enteral feeds was significantly higher, and comprised 23% of overall intake for infants receiving a
0.5 mg bolus dose of phylloquinone after delivery, and 50% of overall intake for infants who received
a 0.2 mg dose. Thus the contribution towards overall phylloquinone intake made by enteral feeding
is small, but becomes more important in infants not given PN and particularly so for infants who
receive lower bolus prophylactic doses (0.2 mg) and who do not receive PN.
These data show that in almost all infants, the average daily phylloquinone intake was in
excess of the currently recommended amounts. The intakes were particularly high at three to four
times the recommended amounts in all who received PN (irrespective of prophylactic dose), and
were approximately twice the recommended amounts in infants given 0.5 mg prophylactic doses
who did not receive PN. Only infants who received the 0.2 mg dose and who did not receive PN
had an intake which approximated well to the current recommended daily phylloquinone intake of
8–10 µg/kg/day. Our data provide further evidence that the amounts of phylloquinone currently
added to manufactured PN multivitamin solutions are excessive for the needs of preterm infants and
should be reviewed.
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Although there are no known clinical manifestations of toxicity from phylloquinone prophylaxis
in neonates, nor indeed any known toxic effects in adults consuming high amounts of vitamin K [7],
we previously found evidence of hepatic overload in a sub-group of preterm infants from our
main study who had received the 0.5 mg rather than the 0.2 mg dose for prophylaxis [9]. The
larger dose was more likely to be associated with elevated serum phylloquinone 2,3-epoxide
concentrations, and suggested overload of the hepatic vitamin K 2,3-epoxide reductase enzyme in
some preterm infants [2,9]. Furthermore, in a separate study we previously obtained evidence of
metabolic overload in a subgroup of preterm infants who predominately excreted the less extensively
metabolised urinary 7C-side chain metabolite of vitamin K instead of the usual 5C-side chain
metabolite [21]. This subgroup also had the highest serum concentrations of phylloquinone together
with raised blood concentrations of phylloquinone 2,3-epoxide that is normally undetectable. This
combination of increased excretion of the 7C-metabolite, high serum phylloquinone and raised
phylloquinone 2,3-epoxide is indicative of a metabolic overload of both vitamin K recycling and
catabolic pathways [21]. None of the infants in these studies who had biochemical evidence of
overload showed any clinical manifestations of an overload status.
Because of their special nutritional requirements preterm babies are often provided with
multivitamin supplements—including the fat-soluble vitamins A, D, and E—at the time of
discharge home from the neonatal unit; these are usually continued throughout infancy. However
post-discharge phylloquinone supplements are rarely provided to this group at present. Yet without
adequate ongoing supplementation preterm infants may be at increased risk of developing vitamin K
deficiency in early infancy, particularly if they continue to be exclusively breast fed. National
surveillance studies of VKDB continue to report sporadic cases in preterm infants [6]. The most
recent study in the United Kingdom and the Irish Republic reported a case of probable VKDB in a
24-week gestation infant who had received 0.4 mg/kg IM at birth [22]. This infant was primarily
human milk fed and had no liver disease but suffered gastro-intestinal bleeding aged three months
postnatal. Further study is required to assess whether phylloquinone supplements should be given
routinely to preterm infants on discharge home from the neonatal unit.
5. Conclusions
In conclusion, this study of phylloquinone intake in the first weeks of life shows that all
preterm infants received at least the minimum daily recommended intake of phylloquinone, but that
most received an excessive intake. These data support the calls for the amount of phylloquinone
added to standard PN multivitamin solutions to be reduced [14,23,24], and also support lower
initial phylloquinone bolus doses being used for prophylaxis at birth [6]. For all infants studied,
a bolus prophylactic phylloquinone dose of 0.2 mg (or ~0.3 mg/kg) was more appropriate than
0.5 mg because it resulted in an average daily intake over the study period closer to the currently
recommended intake amounts. Also, average daily intakes were remarkably close to the currently
recommended intake values in infants given 0.2 mg prophylaxis who did not receive any PN.
In infants who do not receive PN, a 0.2 mg or 0.5 mg bolus dose given at birth represents a significant
proportion of overall phylloquinone intake.
Future research in preterm infants should focus on their post-discharge vitamin K status and
address the question whether additional supplementation with phylloquinone during infancy should
also be routine.
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